Search

Your search keyword '"van Leeuwen, Nienke"' showing total 3 results
Start Over Author "van Leeuwen, Nienke" Journal diabetes
3 results on '"van Leeuwen, Nienke"'

1. The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway

Author

‘t Hart, Leen M., Fritsche, Andreas, Nijpels, Giel, van Leeuwen, Nienke, Donnelly, Louise A., Dekker, Jacqueline M., Alssema, Marjan, Fadista, Joao, Carlotti, Françoise, Gjesing, Anette P., Palmer, Colin N.A., van Haeften, Timon W., Herzberg-Schäfer, Silke A., Simonis-Bik, Annemarie M.C., Houwing-Duistermaat, Jeanine J., Helmer, Quinta, Deelen, Joris, Guigas, Bruno, Hansen, Torben, Machicao, Fausto, Willemsen, Gonneke, Heine, Robert J., Kramer, Mark H.H., Holst, Jens J., de Koning, Eelco J.P., Häring, Hans-Ulrich, Pedersen, Oluf, Groop, Leif, de Geus, Eco J.C., Slagboom, P. Eline, Boomsma, Dorret I., Eekhoff, Elisabeth M.W., Pearson, Ewan R., and Diamant, Michaela

Published
2013
Full Text
View/download PDF

2. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

Author

't Hart, Leen M., Fritsche, Andreas, Nijpels, Giel, van Leeuwen, Nienke, Donnelly, Louise A., Dekker, Jacqueline M., Alssema, Marjan, Fadista, Joao, Carlotti, Francoise, Gjesing, Anette P., Palmer, Colin N.A., van Haeften, Timon W., Herzberg-Schafer, Silke A., Simonis-Bik, Annemarie M.C., Houwing-Duistermaat, Jeanine J., Helmer, Quinta, Deelen, Joris, Guigas, Bruno, Hansen, Torben, Machicao, Fausto, Willemsen, Gonneke, Heine, Robert J., Kramer, Mark H.H., Hoist, Jens J., de Koning, Eelco J.P., Haring, Hans-Ulrich, Pedersen, Oluf, Groop, Leif, de Geus, Eco J.C., Slagboom, P. Eline, Boomsma, Dorret I., Eekhoff, Elisabeth M.W., Pearson, wan R., and Diamant, Michaela

Subjects
Genetic susceptibility -- Research, Glucose metabolism -- Physiological aspects -- Genetic aspects -- Research, Type 2 diabetes -- Risk factors -- Genetic aspects -- Research, Glucagon -- Physiological aspects -- Genetic aspects -- Research, Health
Abstract

The incretin hormone glucagon-like peptide 1 (GLP-I) promotes glucose homeostasis and enhances B-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P ≤ 8.8 x [10.sup.-7]). rs7202877 near CTRB1/2, a known diabetes risk locus, also associated with an absolute 0.51 ± 0.16% (5.6 ± 1.7 mmo/mol) lower A1C response to DPP-4 inhibitor treatment in G-allele carriers, but there was no effect on GLP-1 RA treatment in type 2 diabetic patients (n = 527). Furthermore, in pancreatic tissue, we show that rs7202877 acts as expression quantitative trait locus for CTRB1 and CTRB2, encoding chymotrypsinogen, and increases fecal chymotrypsin activity in healthy carriers. Chymotrypsin is one of the most abundant digestive enzymes in the gut where it cleaves food proteins into smaller peptide fragments. Our data identify chymotrypsin in the regulation of the incretin pathway, development of diabetes, and response to DPP-4 inhibitor treatment., The incretin hormone glucagon-like peptide 1 (GLP-1) is released after a meal by L cells in the distal parts of the gastrointestinal tract, and it potentiates glucose-dependent insulin secretion by [...]

Published
2013
Full Text
View/download PDF

3. The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway.

Author

Hart, Leen M. 't, Fritsche, Andreas, Nijpels, Giel, van Leeuwen, Nienke, Donnelly, Louise A., Dekker, Jacqueline M., Alssema, Marjan, Fadista, Joao, Carlotti, Françoise, Gjesing, Anette P., Palmer, Colin N. A., van Haeften, Timon W., Herzberg-Schäfer, Silke A., Simonis-Bik, Annemarie M. C., Houwing-Duistermaat, Jeanine J., Helmer, Quinta, Deelen, Joris, Guigas, Bruno, Hansen, Torben, and Machicao, Fausto

Subjects
GLUCAGON-like peptide 1, TYPE 2 diabetes treatment, B cells, CELL physiology, HOMEOSTASIS, CD26 antigen, CHYMOTRYPSIN
Abstract

The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances b-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1--stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/ 2; n = 232; all P ≤ 8.8 x 10-7). rs7202877 near CTRB1/2, a known diabetes risk locus, also associated with an absolute 0.51 ± 0.16% (5.6 ± 1.7 mmol/mol) lower A1C response to DPP-4 inhibitor treatment in G-allele carriers, but there was no effect on GLP-1 RA treatment in type 2 diabetic patients (n = 527). Furthermore, in pancreatic tissue, we show that rs7202877 acts as expression quantitative trait locus for CTRB1 and CTRB2, encoding chymotrypsinogen, and increases fecal chymotrypsin activity in healthy carriers. Chymotrypsin is one of the most abundant digestive enzymes in the gut where it cleaves food proteins into smaller peptide fragments. Our data identify chymotrypsin in the regulation of the incretin pathway, development of diabetes, and response to DPP-4 inhibitor treatment. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results